• Authors: Mondal T. et al.
  • Year: 2021
  • Journal: EMBO Mol Med
  • Applications: in vitro / DNA / jetOPTIMUS
  • Cell types:
    1. Name: 4T1
      Description: Malignant neoplasms of the mouse mammary gland cells, also known as 4T1-A
    2. Name: ID8
      Description: Spontaneously transformed  Murine Ovarian Surface Epithelial cell
      Known as: ID8/MOSEC
    3. Name: MC-38


Stable cell line generation: 60-70% confluent cells were transfected in 10 cm dish at 1:1 (DNA:jetOPTIMUS) ratio (w/v): 10 µg plasmid, 10 µl jetOPTIMUS in 1 ml jetOPTIMUS buffer. After 10 incubation at room temperature, complexes were added to the cells.


Lack of effective immune infiltration represents a significant barrier to immunotherapy in solid tumors. Thus, solid tumor-enriched death receptor-5 (DR5) activating antibodies, which generates tumor debulking by extrinsic apoptotic cytotoxicity, remains a crucial alternate therapeutic strategy. Over past few decades, many DR5 antibodies moved to clinical trials after successfully controlling tumors in immunodeficient tumor xenografts. However, DR5 antibodies failed to significantly improve survival in phase-II trials, leading in efforts to generate second generation of DR5 agonists to supersize apoptotic cytotoxicity in tumors. Here we have discovered that clinical DR5 antibodies activate an unexpected immunosuppressive PD-L1 stabilization pathway, which potentially had contributed to their limited success in clinics. The DR5 agonist stimulated caspase-8 signaling not only activates ROCK1 but also undermines proteasome function, both of which contributes to increased PD-L1 stability on tumor cell surface. Targeting DR5-ROCK1-PD-L1 axis markedly increases immune effector T-cell function, promotes tumor regression, and improves overall survival in animal models. These insights have identified a potential clinically viable combinatorial strategy to revive solid cancer immunotherapy using death receptor agonism.